Amicus Therapeutics (NASDAQ:FOLD) Price Target Raised to $17.00

Amicus Therapeutics (NASDAQ:FOLD) had its price target lifted by analysts at JPMorgan Chase & Co. from $16.00 to $17.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 58.88% from the company’s current price.

A number of other research firms have also recently commented on FOLD. Morgan Stanley decreased their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Bank of America lifted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Cantor Fitzgerald increased their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price target for the company. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Stock Up 0.1 %

NASDAQ:FOLD traded up $0.01 during trading hours on Tuesday, reaching $10.70. The company’s stock had a trading volume of 210,383 shares, compared to its average volume of 2,717,181. Amicus Therapeutics has a 12 month low of $9.02 and a 12 month high of $14.57. The stock has a 50 day moving average price of $11.11 and a two-hundred day moving average price of $10.61. The company has a market capitalization of $3.20 billion, a P/E ratio of -31.50 and a beta of 0.68. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.26 and a current ratio of 3.15.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total transaction of $79,500.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $9,398,532.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,398,532.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bradley L. Campbell sold 7,901 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $11,083,175. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,401 shares of company stock valued at $352,038. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Several institutional investors have recently bought and sold shares of FOLD. OLD Second National Bank of Aurora acquired a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $26,000. Hazlett Burt & Watson Inc. boosted its holdings in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the period. Blue Trust Inc. boosted its holdings in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares during the period. Arcadia Investment Management Corp MI purchased a new stake in Amicus Therapeutics during the 3rd quarter worth about $32,000. Finally, Headlands Technologies LLC purchased a new position in shares of Amicus Therapeutics in the 2nd quarter valued at about $89,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.